Hims(US:HIMS)2026-02-23 23:00Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $618 million, representing a year-over-year growth rate of 28% [25] - For the full fiscal year 2025, revenue reached $2.35 billion, reflecting a year-over-year growth rate of 59% [25] - Adjusted EBITDA for 2025 increased nearly 80% year-over-year to $318 million, with an Adjusted EBITDA margin of 14% [31] - Net income for the full year increased to $128 million, compared to the previous year [34] Business Line Data and Key Metrics Changes - The Hims brand in the US saw over 30% year-over-year revenue growth in 2025, despite a pivot away from generic sexual solutions [26] - The Hers brand continued to display triple-digit revenue growth, accounting for nearly 40% of U.S. revenue [27] - Approximately 65% of subscribers were utilizing a personalized treatment by the end of 2025, with monthly revenue per average subscriber increasing 11% year-over-year to $83 [24][25] Market Data and Key Metrics Changes - International revenue grew almost 400% year-over-year to $134 million, with expectations for this segment to become a more meaningful portion of overall revenue [30] - The company expects at least $200 million in revenue contributions from international markets in 2026, including from the acquisition of Eucalyptus [48] Company Strategy and Development Direction - The company aims to achieve $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030, focusing on consumer-centric healthcare [22] - Investments in technology and infrastructure are prioritized to enhance personalized care and expand operational capabilities [19][38] - The company plans to deepen its international presence and aims for a unified brand across major markets within the next 1-2 years [54] Management's Comments on Operating Environment and Future Outlook - Management believes the healthcare system must evolve towards a consumer-oriented model, similar to platforms like Netflix and Spotify [6] - The company is confident in its ability to navigate regulatory scrutiny and maintain growth through diverse offerings beyond GLP-1 treatments [56] - Management anticipates strong demand for weight loss solutions and expects subscriber growth to remain robust throughout 2026 [45] Other Important Information - The company has invested over $300 million in facilities over the last three years, expanding its operational footprint to over 1 million square feet [19] - The acquisition of Eucalyptus is expected to enhance the company's international capabilities and contribute significantly to revenue growth [43] Q&A Session Summary Question: What are the long-term priorities for global growth with the acquisition of Eucalyptus? - The company aims to target 10 key markets globally and achieve over $1 billion in incremental international revenue within a few years [54] Question: How will the company manage risks from potential regulatory scrutiny on GLP-1s? - Management emphasizes that the majority of revenue comes from offerings outside of weight loss and plans to continue expanding its diverse offerings [56]